MA46620A - Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha - Google Patents
Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alphaInfo
- Publication number
- MA46620A MA46620A MA046620A MA46620A MA46620A MA 46620 A MA46620 A MA 46620A MA 046620 A MA046620 A MA 046620A MA 46620 A MA46620 A MA 46620A MA 46620 A MA46620 A MA 46620A
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- responses
- useful
- ifn alpha
- heterobicyclic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414158P | 2016-10-28 | 2016-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46620A true MA46620A (fr) | 2021-05-26 |
Family
ID=60263169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046620A MA46620A (fr) | 2016-10-28 | 2017-10-27 | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10781215B2 (enExample) |
| EP (1) | EP3532473B1 (enExample) |
| JP (1) | JP7145850B2 (enExample) |
| KR (1) | KR102477063B1 (enExample) |
| CN (1) | CN110114357B (enExample) |
| ES (1) | ES2895107T3 (enExample) |
| MA (1) | MA46620A (enExample) |
| WO (1) | WO2018081488A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| TW201940483A (zh) | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶２介導的傳訊之抑制劑 |
| TWI800696B (zh) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| EA202192625A1 (ru) * | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
| CA3138473A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| MX2022005563A (es) | 2019-11-08 | 2022-08-19 | Ventyx Biosciences Inc | Ligandos de la pseudoquinasa tyk2. |
| WO2021108803A1 (en) * | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| CN116283993B (zh) * | 2021-12-20 | 2024-05-03 | 艾立康药业股份有限公司 | 一种嘧啶类化合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| EP2188292B1 (en) | 2007-08-08 | 2013-05-29 | GlaxoSmithKline Intellectual Property Development Limited | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
| US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| AU2009238590A1 (en) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US9540333B2 (en) * | 2012-11-08 | 2017-01-10 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNα |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP3080131B1 (en) * | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| WO2015175813A1 (en) | 2014-05-14 | 2015-11-19 | The Regents Of The University Of Colorado, A Body Corporate | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
-
2017
- 2017-10-27 MA MA046620A patent/MA46620A/fr unknown
- 2017-10-27 WO PCT/US2017/058645 patent/WO2018081488A1/en not_active Ceased
- 2017-10-27 KR KR1020197014828A patent/KR102477063B1/ko active Active
- 2017-10-27 ES ES17794645T patent/ES2895107T3/es active Active
- 2017-10-27 US US16/344,459 patent/US10781215B2/en active Active
- 2017-10-27 EP EP17794645.6A patent/EP3532473B1/en active Active
- 2017-10-27 CN CN201780080803.4A patent/CN110114357B/zh active Active
- 2017-10-27 JP JP2019522803A patent/JP7145850B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019532092A (ja) | 2019-11-07 |
| US20190322672A1 (en) | 2019-10-24 |
| EP3532473A1 (en) | 2019-09-04 |
| WO2018081488A1 (en) | 2018-05-03 |
| KR102477063B1 (ko) | 2022-12-12 |
| ES2895107T3 (es) | 2022-02-17 |
| JP7145850B2 (ja) | 2022-10-03 |
| CN110114357B (zh) | 2022-05-31 |
| US10781215B2 (en) | 2020-09-22 |
| CN110114357A (zh) | 2019-08-09 |
| KR20190068614A (ko) | 2019-06-18 |
| EP3532473B1 (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46620A (fr) | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha | |
| MA46453A (fr) | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| EP3356356A4 (en) | COMPOUNDS AS TRPM8 MODULATORS | |
| EP3383447A4 (en) | LIGHT-ACTIVATED HYDROGEL PRODUCTION | |
| EP3509581A4 (en) | FORMULATIONS OF (R | |
| MA43512A (fr) | Composés hétérocycliques utiles en tant que modulateurs du tnf alpha | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| BR112016025470A2 (pt) | ?hdl terapêutico? | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| EP3474667A4 (en) | SMALL MOLECULAR MODULATORS OF PANTOTHENAT KINASES | |
| EP3528813A4 (en) | P2X3 AND / OR P2X2 / 3 CONNECTIONS AND METHOD | |
| EP3400026A4 (en) | VISCOSITY AND STABILITY-MODIFIED ULTRASOUND GEL | |
| MA48602A (fr) | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha | |
| MA43314A (fr) | Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| MA44772A (fr) | 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t | |
| EP3316879A4 (en) | TOPICAL DIACEREIN OR RHEIN FORMULATIONS AND USES THEREOF | |
| DK3279312T3 (da) | Biobeskyttelse af mejeriprodukter | |
| FR3037236B1 (fr) | Microcapsules et composition de maquillage ou de tatouage thermochromiques | |
| MA41120A (fr) | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci | |
| EP3459369A4 (en) | PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SP. KCCM 11826P STRAIN FOR PREVENTING HYPERPHOSPHATMA AND TREATING CHRONIC KIDNEY DISEASE AND HEALTH FUNCTIONAL FOOD | |
| EP3897615A4 (en) | CANNABIS COMPOSITIONS AND METHODS | |
| EP3609963A4 (en) | UNIVERSAL COLOR COMPOSITION | |
| EP3265177C0 (en) | Formulations of hydrophilic compounds |